.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
A 2026 post hoc analysis of phase 3 retinal vein occlusion trials examined whether the time between diagnosis of macular edema and the first intravitreal aflibercept injection influenced visual and anatomic outcomes. Patients were grouped by treatment delay, allowing comparison across central and branch retinal vein occlusion populations. The analysis reflects an important practical principle in retinal vascular disease: prolonged edema can lead to structural damage that limits visual recovery even when effective therapy is eventually started. Although post hoc studies cannot prove causation and treatment timing may be influenced by baseline disease severity or healthcare access, the findings support the value of timely diagnosis, OCT assessment, and treatment initiation. For HCPs, this is especially relevant in systems where referral or access to intravitreal therapy may create delays. The paper also highlights why baseline vision should be considered when setting expectations. Patients presenting early with better starting acuity may have different absolute gains than those presenting after substantial visual loss. Overall, the evidence supports minimizing avoidable treatment delays while tailoring anti-VEGF plans to disease severity and response.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A 2026 post hoc analysis of phase 3 retinal vein occlusion trials examined whether the time between diagnosis of macular edema and the first intravitreal aflibercept injection influenced visual and anatomic outcomes. Patients were grouped by treatment delay, allowing comparison across central and branch retinal vein occlusion populations. The analysis reflects an important practical principle in retinal vascular disease: prolonged edema can lead to structural damage that limits visual recovery even when effective therapy is eventually started. Although post hoc studies cannot prove causation and treatment timing may be influenced by baseline disease severity or healthcare access, the findings support the value of timely diagnosis, OCT assessment, and treatment initiation. For HCPs, this is especially relevant in systems where referral or access to intravitreal therapy may create delays. The paper also highlights why baseline vision should be considered when setting expectations. Patients presenting early with better starting acuity may have different absolute gains than those presenting after substantial visual loss. Overall, the evidence supports minimizing avoidable treatment delays while tailoring anti-VEGF plans to disease severity and response.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
